Twenty-four weeks of treatment could be sufficient to cure between 93 and 100 percent of treatment-naive chronic hepatitis C virus (HCV) genotype 1 (G1) infected patients if they have a fast antiviral response to telaprevir with peginterferon and ribavirin , according to new research.